Overview
Primary Objective:
To characterize the patients who receive Dupixent (dupilumab) for AD in a real-world
setting, with respect to their medical history, socio-demographic and disease
characteristics, and prior and concomitant treatments of AD
Secondary Objectives:
- To characterize real-world use patterns of Dupixent for AD (eg, used regimens, reason for initiation of new treatments, concomitant therapies, treatment durations and reasons for discontinuation and/or switching)
- To assess the long-term effectiveness of Dupixent in adult AD patients in a real-world setting
- To assess comorbid atopic conditions and effects of treatment in comorbid atopic conditions in adult patients who receive Dupixent for AD
- To collect safety data on study participants
Description
Participants enrolled in the study will be followed for 5 years.
Eligibility
Inclusion criteria:
- Initiating treatment with Dupixent for AD according to the country-specific prescribing information. Note: Participants may be eligible if they have already initiated treatment with Dupixent for AD within 6 months before their enrollment in the registry, provided that all core baseline data required (Eczema Area and Severity Index [EASI], Scoring of Atopic Dermatitis [SCORAD], body surface area [of AD involvement] [BSA], Patient-Oriented Eczema Measure [POEM], and Dermatology Life Quality Index [DLQI]) by the registry protocol were captured at the time of initiating Dupixent treatment and are available for entry in the registry database
- Able to understand and complete study-related questionnaires
- Provide signed informed consent
Exclusion criteria:
- Participants who have a contraindication to the drug according to the country-specific prescribing information label
- Any condition that, in the opinion of the investigator, may interfere with patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other co-morbidities that can predictably prevent the participant patient from adequately completing the schedule of visits and assessments
- Patients currently participating in any interventional clinical trial which modifies patient care
The above information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial.